CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac...
– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – –...
- Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization...
CHARLESTOWN, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...
- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - - New Innovative Licensing and Access Pathway (ILAP) designation...
CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac...
- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet...
CHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...
In a report released today, Sami Corwin from William Blair maintained a Buy rating on Solid Biosciences. The company’s shares opened today at $6.06.Elevate Your Investing Strategy: Take advantage of...
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac...